Prognomix is a private research-based company focused on the discovery of genetic signatures associated with the complications of Type II Diabetes. The company plans to develop and market molecular diagnostic kits for the testing of diabetes complications. The company is concentrating on developing a molecular diagnostic test pertinent for detection of risks to develop renal, ocular, cardiac, cerebral, vascular and other complications of diabetic disease. This market is vast and estimated to be around $24 billion in the United States alone.
Funding Rounds (1) - $4.1MUpdate
Board Members and Advisors (1)Update
|Mar 17, 2010||bdc.ca - Prognomix raises 4100000 in unknown round|
4101, rue Molson, bureau 201
Çan, Canakkale H1Y 3L1